A randomized phase Ill double blinded placebo controlled trial of aspirin as adjuvant therapy for HER2 negative breast cancer: The ABC trial
Brief description of study
The primary purpose of the study is to determine the effectiveness of the aspirin among early stage node-positive HER2 negative breast cancer patients, who have completed the usual chemotherapy, surgery, and/or radiation therapy for breast cancer. We want to know if taking aspirin once per day will have a lower rate of cancer come back. Aspirin is approved by the FDA, but is not approved for the purpose of lowering risk of breast cancer coming back or improving survival.
Clinical Study Identifier: s18-01759
ClinicalTrials.gov Identifier: NCT02927249
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
